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Introduction
Glioma is the most common supratentorial brain tumor affecting approximately 138,000 individuals in the United States in 2010, with an annual incidence of 17,000 new cases [1] . Despite significant advances in surgical, radiation, and medical therapies, the prognosis of this disease remains dismal, with a median survival of less than 2 years for the most malignant form, glioblastoma [2] . A number of biological, clinical, and diagnostic factors account for the poor prognostic outcomes of patients with glioma. One factor that directly impacts the diagnosis of glioma is tumoral biological heterogeneity.
The pathologic assessment of glioma relies on an invasive procedure for tissue sampling that is often performed without regard for tumor biological heterogeneity. The assessment of tumor aggressiveness based on isolated regional tissue samples can lead to sampling error, resulting in undergrading, with a published report in up to 30% of cases [3, 4] . The inherent limitations of histologic techniques to assess tumor grade have led to the development of imaging-based methods for the noninvasive quantification of aggressive biological characteristics.
Recent advances in magnetic resonance imaging (MRI) have provided for the acquisition of physiological metrics with the potential to noninvasively assess biological characteristics that influence the tumor grade and the clinical prognosis of patients with glioma.These physiological MRI sequences contribute data that complement the standard information provided by traditional morphologic T1-and T2-weighted techniques. One recently developed physiological sequence is spin-lattice relaxation in the rotating frame (T1ρ). T1ρ allows for the quantitative assessment of spin-lock contrast within tissues [5] . Aronen et al. have previously published a case series of T1ρ imaging obtained at 0.1-T field strength in a cohort of 11 patients with high-grade glioma and concluded that spin-lock contrast maps have the potential to improve tissue biological characterization. Therefore, the specific aim of this case report was to describe our initial experience with the use of T1ρ MRI in characterizing glioblastoma biological heterogeneity.
Case report
An 84-year-old man presented to our institution on April 2014 with a right frontal temporal mass lesion (Fig. 1) . Relevant past medical history included adenocarcinoma of the left lung, for which the patient had undergone lobectomy on August 2013.
On September 2013, the patient experienced a brief episode of vertigo that resulted in a fall from standing. MRI of the brain demonstrated a nonenhancing T2 hyperintense mass centered within the right frontal operculum with regional extension including the anterior cingulate gyrus. The patient underwent a short-interval follow-up MRI on October 2013 that was unchanged. Imaging on March 2014 demonstrated a progression of a presumed, but not pathologically confirmed, glioma evidenced by focal contrast enhancement, now within the orbitofrontal gyri. At another institution, the patient underwent burr hole tissue sampling from within the peripheral nonenhancing margin involving the superior frontal gyrus white matter. The lack of infiltrative tumor cells resulted in the sample being classified as nondiagnostic (Fig. 2, center left image) .
On April 2014, the patient presented to our institution's Neurological Surgery service for image-guided tissue sampling and subsequent therapy. Standard preoperative MRI using a 3.0-T scanner (Discovery; GE Healthcare, Waukesha, WI) was obtained 24 hours before the tissue sampling procedure ( [6] [7] [8] ; Fig. 1 and Fig. 2) .
A magnetization-prepared 3-dimensional pseudo-steadystate fast spin-echo acquisition pulse sequence was used for T1ρ quantification. T1ρ imaging parameters included 0.9 × 0.9 × 1.6 mm resolution, 280 × 196 mm field of view, 120 slices, 0.5 number of excitations, 2× Autocalibrating Reconstruction for Cartesian parallel imaging (GE Healthcare) along the phase encoding direction, an echo train length of 132, a spin-lock frequency of 500 Hz, and a time of spin lock of 2, 10, 40, 60, 80, and 100 ms. The total scan time for T1ρ data acquisition was 3.5 minutes. T1ρ imaging was performed before the intravenous administration of 0.1 mmol/kg gadopentetate dimeglumine (Gd-DTPA; Magnevist, Bayer HealthCare Pharmaceuticals).
T1ρ image processing was performed offline using a commercially available postprocessing workstation (Advantage Workstation, GE Healthcare) and software (FuncTool 9.4.05a, GE Healthcare), allowing for the generation of quantitative whole-brain spin-lock contrast maps ( Fig. 1 and Fig. 2 ) that could be integrated into the stereotactic image-guided procedure (Brainlab, VectorVision Navigation System).
Anatomic and physiological MRI was used to guide the prospective selection of tissue sampling sites felt most likely to represent a bulk tumor that would allow for a definitive diagnosis of disease etiology. Two sampling sites were preoperatively planned utilizing the surgical navigation workstation (Brainlab, VectorVision Navigation System). Criteria used to plan sites were based upon results from previous studies as having either a relative cerebral blood volume of >3, an apparent diffusion coefficient of <1200, and a Cho to N-acetyl aspartate index of >2.0; however, this provided for only a target within the subinsular white matter that was not radially accessible by a right transfrontal stereotactic approach [8, 9] . Tissue sampling was performed as close to the target of interest yielding a single diagnostic sample (Fig. 3) . A retrospective evaluation of the T1ρ map demonstrated a nonenhancing region within the anterior cingulate with markedly elevated spin-lock contrast metrics (T1ρmin = 110, T1ρmean = 244, T1ρmax = 352) above background normalappearing white matter (NAWM; T1ρmin = 62, T1ρmean = 89, T1ρmax = 126). Relative T1ρ values within the anterior cingulate gyrus were calculated as the ratio of the lesion to the NAWM (rT1ρmin = 1.77, rT1ρmean = 2.74, rT1ρmax = 2.79). Interrogation of the T2 hyperintense nonenhancing white matter adjacent to the prior nondiagnostic tissue sampling site within the right superior frontal gyrus demonstrated lesion T1ρ values (T1ρmin = 102, T1ρmean = 126, T1ρmax = 165) that were only mildly elevated with respect to NAWM (T1ρmin = 59, T1ρmean = 85, T1ρmax = 122) (Fig. 2) . This finding provided for rT1ρ values that were less than the similarappearing nonenhancing T2 hyperintense lesion within the anterior cingulate gyrus (rT1ρmin = 1.73, rT1ρmean = 1.48, rT1ρmax = 1.35) (Fig. 4) .
Intraoperative stereotactic magnetic resonance-guided tissue sampling of the nonenhancing T2-fluid-attenuated inversion recovery hyperintense region involving the anterior cingulate gyrus with elevated T1ρ metrics provided a pathologic diagnosis of glioblastoma with a Ki-67 score of 40% (Fig. 5) . Given the high diagnostic yield of this tissue sample, no additional samples were obtained. The patient subsequently recovered well from the procedure and was discharged on postoperative day 5. Surgical debulking of the tumor was not performed because of the extent and the location of the disease. The patient is currently undergoing radiotherapy (2 Gy/day, 5 days/week for 6 weeks, total dose of 60 Gy) and temozolomide-based medical therapy (75 mg/m 2 /day for 42 days followed by 150 mg/m 2 /day for 5 consecutive days over 28 days for 6 cycles).
Discussion
This case report highlights our initial experience in using T1ρ MRI to differentiate similar-appearing nonenhancing regions of T2 hyperintensity caused by a biologically aggressive glioblastoma from regions of non-tumor infiltrated vasogenic edema. The nonenhancing tissue sampling site comprising vasogenic edema without tumor demonstrated T1ρ values that were only slightly elevated from NAWM (Fig. 3) . Conversely, the nonenhancing tissue sampling site comprising glioblastoma had mean and maximum T1ρ values almost 3fold higher than NAWM. To our knowledge, this is the first report of T1ρ MRI directly characterizing an aggressive biological process heterogeneously occurring within a patient with glioblastoma. We provide pathologic confirmation that T1ρ imaging differs regionally within glioblastoma when compared to reactive white matter changes resulting from vasogenic edema. T1ρ was initially described within solid-state materials by Redfield [10, 11] . To date, clinical applications of this MRI technique has been most widely applied to evaluating the hydration status of human articular cartilage. However, the neurologic applications of T1ρ MRI have been explored in patients with ischemia, neurodegenerative disorders, and brain tumors, and as a response assessment to gene therapy within glioma mouse models [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] . T1ρ MRI obtains tissue contrast through the quantification of spin-lattice relaxation in the rotating frame. This technique allows for the measurement of low-frequency processes at clinical MRI field strengths [24, 25] . This measurement is achieved by first flipping the spin magnetization into the transverse plane by a 90°radiofrequency pulse. Next, a spinlock pulse (low-powered B1 radiofrequency pulse) is applied parallel to the magnetic moment. The spin-locked magnetization then relaxes with a time constant T1ρ during the application of the spin-lock pulse. T1ρ dispersion is then measured by varying the B1 field amplitude within a constant Bo field. This technique allows for the measurement of spin interaction and motional processes that occur at very low frequency components (100 Hz to a few kilohertz).
The biological etiology of differential T1ρ relaxation within glioma has not been fully adjudicated; however, proton chemical exchange (pH), dipole-dipole interactions, spin-spin coupling, diffusion, and slow rotational motions of spins on large macromolecules have been postulated to contribute in various degrees [26] . Histologically, within cartilage specimens, variation in the T1ρ relaxation is hypothesized primarily to be due to the hydration status and the interaction between the restricted water pool and the free water pool [27] .
Within glioma, we hypothesize that variation in T1ρ relaxation is similarly related to the interaction between free and bound water molecules. The observation of elevated T1ρ associated with biologically aggressive glioblastoma tissues may be multifactorial; however, a predominating factor may be due to the degree of vasogenic edema. Within glioblastoma, a hypoxia-mediated vascular endothelial growth factor expression has been shown to upregulate neovascularization [28] . This results in deregulated angiogenesis, endothelial proliferation, and increased capillary permeability. The increase in local capillary endothelial permeability results in an immediate increase in the interstitial nutrient supply that facilitates tumor growth. However, this also results in interstitial hydration (vasogenic edema) manifested by T2/FLAIR prolongation on MRI. The tissue contrast provided by T1ρ imaging may provide a quantifiable map of tissue hydration status not possible by FLAIR or T2-weighted sequences. Future applications of T1ρ imaging could include reducing tissue sampling error and undergrading within nonenhancing gliomas.
The observations of this case report are inherently limited. Further prospective studies adjudicating the biological influences and clinical significance of T1ρ MRI in patients diagnosed with glioma are needed. One possible obstacle to overcome with T1ρ imaging is its propensity to cause tissue heating. Prior studies have suggested the high specific absorption rate that occurs during prolonged spin-lock pulses may be an impediment to the widespread clinical application of T1ρ MRI [29, 30] . We have decreased the likelihood of tissue heating by limiting the spin-lock time to a maximum of 100 ms.
Conclusion
The observations of this case report suggest that it is feasible to integrate T1ρ MRI into the clinical evaluation for biologically aggressive regions within glioblastomas. Figs. 1, 2 and 4) demonstrates microvascular proliferation (arrows) and a markedly increased cellular proliferation (brown-stained cells) characteristic of biologically aggressive features diagnostic of glioblastoma.
